Dublin-headquartered biopharmaceutical company Jazz Pharmaceuticals has appointed Erica Jefferson as its first Chief Communications Officer, creating a unified communications function that brings together the company's external and employee communications under a single leadership structure.
Jefferson will report to President and CEO Renee Gala and work closely with the company's investor relations and transformation teams as Jazz advances its corporate strategy and stakeholder engagement efforts.
"She brings a patient-centric approach to communications, has a reputation for leading and building high-performing teams, and applying her diverse communications experience to build and strengthen corporate and brand awareness," Gala said in a LinkedIn post announcing the appointment.
Jefferson joins Jazz after serving as an Advisory Council Member at Real Chemistry, where she advised clients on strategic communications, public affairs, thought leadership and regulatory issues. She previously held senior leadership roles as Senior Vice President of Corporate Affairs at ReCode Therapeutics and Associate Commissioner in the U.S. Food and Drug Administration's Office of External Affairs.
Commenting on the appointment, Gala said Jefferson's team will play a key role in evolving how Jazz is perceived by its stakeholders as the biopharmaceutical company pursues its long-term growth ambitions.
